ArticleInternational dental journal2026
Clinical Outcomes of Polidocanol Foam Sclerotherapy in Treatment of Sublingual Ranula.
Article in International dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
aimsRanula is a mucus retention cyst originating from the sublingual gland, and surgical intervention has traditionally been the main treatment. However, surgery is often associated with recurrence, risk of nerve injury, and patient discomfort. Sclerotherapy using polidocanol, a low-toxicity agent, has emerged as a promising minimally invasive alternative. This study aimed to evaluate the clinical outcomes and safety of polidocanol injection therapy in patients with sublingual ranula.
methodsThis retrospective study included 34 patients with sublingual ranula who underwent intralesional injection of 3% polidocanol between December 2021 and March 2025. Some patients with large or recurrent lesions were additionally treated with pingyangmycin. Clinical data including age, sex, lesion size, symptom duration, number of injections, and follow-up time were collected. Treatment outcomes were categorized as complete resolution or unfavorable outcomes (including partial remission or recurrence). Statistical analyses were performed to identify factors associated with treatment outcomes.
resultsAmong the 34 patients, 30 (88.2%) achieved complete resolution, while 4 (11.8%) had unfavorable outcomes. Maximum lesion diameter was independently associated with treatment outcome (adjusted OR per 1-mm increase = 0.886, 95% CI: 0.742-0.982; P = .018; Firth-penalized logistic regression adjusted for age and lesion site). No serious complications were observed during a mean follow-up of 22.44 ± 14.93 months.
conclusionPolidocanol injection therapy appears to be a safe and minimally invasive option for the management of sublingual ranula, demonstrating favorable clinical outcomes and a high rate of lesion resolution in this retrospective cohort. CLINICAL RELEVANCE: Polidocanol sclerotherapy offers a conservative outpatient treatment option for sublingual ranula, providing favorable clinical outcomes with low morbidity and potentially reducing the need for surgical excision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.